key: cord-0972149-ql12qa6g
authors: Schuhenn, J.; Meister, T.L.; Todt, D.; Bracht, T.; Schork, K.; Billaud, J.-N.; Elsner, C.; Heinen, N; Karakoese, Z.; Haid, S.; Kumar, S.; Brunotte, L.; Eisenacher, M.; Chen, J.; Yuan, Z; Pietschmann, T.; Wiegmann, B.; Beckert, H.; Taube, C.; Le-Trilling, VTK.; Trilling, M.; Krawczyk, A.; Ludwig, S.; Sitek, B.; Steinmann, E.; Dittmer, U.; Sutter, K.; Pfaender, S.
title: Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection
date: 2021-05-20
journal: bioRxiv
DOI: 10.1101/2021.05.20.444757
sha: 12e3c00758a390eb5960d442e0fa878c481d0cfb
doc_id: 972149
cord_uid: ql12qa6g

Type I interferons (IFN-I) exert pleiotropic biological effects during viral infections, balancing virus control versus immune-mediated pathologies and have been successfully employed for the treatment of viral diseases. Humans express twelve IFN-alpha (α) subtypes, which activate downstream signalling cascades and result in distinct patterns of immune responses and differential antiviral responses. Inborn errors in type I IFN immunity and the presence of anti-IFN autoantibodies account for very severe courses of COVID-19, therefore, early administration of type I IFNs may be protective against life-threatening disease. Here we comprehensively analysed the antiviral activity of all IFNα subtypes against SARS-CoV-2 to identify the underlying immune signatures and explore their therapeutic potential. Prophylaxis of primary human airway epithelial cells (hAEC) with different IFNα subtypes during SARS-CoV-2 infection uncovered distinct functional classes with high, intermediate and low antiviral IFNs. In particular IFNα5 showed superior antiviral activity against SARS-CoV-2 infection. Dose-dependency studies further displayed additive effects upon co-administered with the broad antiviral drug remdesivir in cell culture. Transcriptomics of IFN-treated hAEC revealed different transcriptional signatures, uncovering distinct, intersecting and prototypical genes of individual IFNα subtypes. Global proteomic analyses systematically assessed the abundance of specific antiviral key effector molecules which are involved in type I IFN signalling pathways, negative regulation of viral processes and immune effector processes for the potent antiviral IFNα5. Taken together, our data provide a systemic, multi-modular definition of antiviral host responses mediated by defined type I IFNs. This knowledge shall support the development of novel therapeutic approaches against SARS-CoV-2.

Without the capacity to produce or recognize interferons (IFN), mammalian hosts rapidly 27 succumb in case of viral infections. Accordingly, humans with loss-of-function mutations in 28 the IFN signalling pathway even fail to control attenuated viruses. Therefore., IFNs are 29 indispensable mediators of the first immediate intrinsic cellular defences against invading 30 pathogens, such as viruses. So far, three different types of IFNs, types I, II and III, have been 31 identified and classified based on their genetic, structural, and functional characteristics as well 32 as receptor usages 1-3 . Type I IFNs are among the first line of antiviral defence due to the 33 ubiquitous expression of the surface receptor IFNAR consisting of two subunits IFNAR1 and 34 IFNAR2. In humans, the type I IFN family comprises IFNβ, IFNε, IFNκ, IFNω and twelve 35

IFNα subtypes. The latter code for the distinct human IFNα proteins: IFNα1, and -21, encoded by 14 nonallelic genes including one pseudogene and two 37 genes that encode identical proteins (IFNα13 and IFNα1). The overall identity of the IFNα 38 proteins ranges from 75 to 99% amino acid sequence identity 1,4 . Despite their binding to the 39 same cellular receptor, their antiviral and antiproliferative potencies differ considerably 5-10 . As 40 a general event in terms of signal transduction, IFNα subtypes engage the IFNAR1/2 receptor 41 and initiate a signal transduction cascade resulting in the phosphorylation of receptor-associated 42 janus tyrosine kinases culminating in downstream signalling events including the activation of 43 IFN-stimulated gene factor 3 (ISGF3) consisting of phosphorylated STAT1 and STAT2 and 44 the IFN regulatory factor 9. ISGF3 binding to the IFN-stimulated response elements (ISRE), in 45 promotor regions of various genes, initiates the transcriptional activation of a large number of 46 IFN-stimulated genes (ISGs), which elicit direct antiviral, anti-proliferative and 47 post stimulation cellular RNA was sequenced on an Illumina NovaSeq 6000 and differentially 130 expressed genes were sent to Ingenuity Pathway Analysis (IPA; Qiagen) for biological analysis. 131

In order to investigate cellular responses following viral infection, we included SARS-CoV-2-132 infected hAECs (18 h p.i.) in our analysis. Global transcriptomic analysis revealed unique 133 differentially expressed genes (DEGs), both up-and downregulated upon IFN-treatment 37,38 134 for each IFN (Extended Data Figure 3A ) compared to mock-treated cells. Similar to the 135 observed antiviral effects, a general clustering was apparent which showed similar expression 136 patterns for low to intermediate antiviral subtypes (IFNα1, and intermediate 137 to high antiviral subtypes (IFNα2, . Interestingly, we observed a clear 138 difference in the numbers of significantly up-and down-regulated genes after treatment with 139

IFNα subtypes compared to mock-treated cells, which positively correlated with antiviral 140 activity (Extended Data Figure 3B ). Gene ontology (GO) pathway analysis revealed higher 141 expression of genes mostly involved in antiviral immune response amongst the medium and 142 high antiviral subtypes, as well as pathways which can be associated with protein localization, 143 translation, oxidative phosphorylation, RNA metabolism, ER stress, signalling pathways and 144 lymphocyte activation ( Figure 2A ). Strikingly, different IFNα subtypes displayed unique GO 145 patterns with IFNα17, in contrast to other subtypes, regulating genes involved in translation, 146 whereas the treatment with IFNα5 resulted in the strongest regulation of genes associated to 147 signalling pathways and lymphocyte activation among all IFNs (Figure 2A ). We next focussed 148 on genes associated with antiviral responses ( Figure 2B ). A separation based on antiviral 149 activity could be discerned with weak antiviral IFNα subtypes (IFNα1, -6, -16, -10) exhibiting 150 comparatively lower expression values of specific ISGs, whereas medium to strong antiviral 151 IFNα subtypes induced higher expression ( Figure 2B ). We observed two clusters that differed 152   between low and intermediate to high IFN subtypes, with ISG15, IFI27, MX1 and others  153 showing generally lower expression values in the low antiviral IFN subtypes. Even more 154 pronounced were expression changes of IFIT2, IFIT1 and MX2 and others which resulted in a down-regulation for the low-and an upregulation for the intermediate to high antiviral IFN 156 subtypes. As we aimed at identifying immune signatures that correlate with the antiviral activity 157 against SARS-CoV-2 infection, we next evaluated DEGs with respect to distinct, intersecting 158 and common genes amongst and between subtypes (Extended Data Figure 4A ). We identified 159 several differentially expressed genes for each subtype, with IFNα5 expressing most unique 160 genes (1018 DEGs), followed by IFN λ3 (670 DEGs) ( Figure 2C , Extended Data Figure 4B) ). 161

A comparison between high, medium and low antiviral subtypes revealed that 19 genes were 162 commonly differentially expressed amongst all subtypes including Mx1 and OAS2 ( Figure 2D ). 163

The most striking differences could be observed for MX1 and OAS2, which expression levels 164 clearly separated high, intermediate and low antiviral IFN subtypes ( Figure 2D ). Interestingly, 165 42 genes were differentially regulated in the high antiviral group including RNaseL and genes 166 associated with regulation of transcription, signal transduction and metabolic processes ( Figure  167 2E), as well as long non-coding RNAs. In conclusion, we could clearly demonstrate IFN 168 subtype-specific immune signatures that could contribute to the observed differences in 169 antiviral activity. 170 171

Our transcriptomic analysis revealed IFNα subtype-specific distinct, intersecting and common 173 expression patterns of DEGs that most likely contribute to the differential biological activity 174 against SARS-CoV-2. To further uncover relevant cellular effector proteins for the antiviral 175 activity against SARS-CoV-2, we additionally performed proteomic analysis on hAECs pre-176 treated with IFNs. Since we had observed the strongest antiviral activity for IFNα5 and IFNλ3 177 we decided to further investigate their specific proteomic profile in direct comparison with 178

IFNα7, which exhibited a moderate antiviral effect, and IFNα16, displaying a weak effect 179 against SARS-CoV-2 infection, in order to identify key antiviral pathways, crucial in 180 controlling coronavirus infection. To this end, primary hAECs were pre-treated with selected to investigate potential antiviral mechanisms and potential intervention by viral effectors 185 (Extended Data Figure 5A ). Principal component analysis (PCA) revealed a clustering 186 according to donor and/or infection and time points (Extended data Figure 5B -D, Extended 187 Data Table 2 ). In addition to host cell proteins, various viral peptides were identified, which 188 correlate to viral titres depending on the respective donor (Extended Data Table 3 Table 5 ). In contrast, the strongest 213 biological effects on antiviral immune responses after treatment with IFNα5 and -λ3, e.g. IFN 214 signalling as well as antigen presentation, NF-κB signalling or lymphocyte regulation were not 215 affected by viral infection. Interestingly, proteins belonging to other pathways e.g. antigen 216 presentation by MHC class I or proteolysis, seemed to be less abundantly represented under 217 viral infection in the IFNα5 treated samples, a phenomenon which was not as prominent after 218 treatment with IFNλ3 ( Figure 3E , Extended Data Figure 7D ). STRING analysis ( Figure 3F ) 219 highlighted the presence of antiviral key effector molecules (e.g. ISG20, ISG15, IFI44L, IFIT2, 220 IFIT3, IFI35, PML, SP100), which are involved in type I IFN signalling pathways, negative 221 regulation of viral processes and immune effector processes amongst the most potent antiviral 222

IFNs. In conclusion, we identified a variety of antiviral cellular effector molecules that correlate 223 with antiviral activity and controlling coronavirus infection 224 225 Therapeutic potential of IFNα subtypes 226

Currently, there are only a few approved specific antiviral drugs (e.g. monoclonal 227 antibodies) 39,40 for the treatment of COVID-19, which severely limit treatment options during 228 severe clinical courses. Remdesivir, a nucleotide-analogous RNA dependent RNA Polymerase 229 (RdRP) inhibitor originally developed as antiviral against Ebola virus, received an emergency 230 use-approval against COVID-19 and has been employed in the clinics. Unfortunately, due to 231 lack of evidence for recovery of critically ill patients, it is no longer recommended by the World 232

Health Organization (WHO) as single treatment for COVID-19 41 ). Therefore, alternative 233 therapeutic approaches such as combination therapies are urgently needed. As we have 234 observed the strongest antiviral effect in this study for IFNα5 we explored its therapeutic 235 potential in comparison and in combination with remdesivir. In regard to patients viewed as an 236 entity, prophylactic treatment with IFNs is no clinical option. Nevertheless, a treatment initiated 237 following diagnosis can still 'prophylactically' condition and protect cells in the body against 238 later infection events. To monitor the kinetics of the antiviral activity of IFNα subtypes, we 239 treated cells either before infection ('pre-') or up to 8 h post infection ('post-') and studied the 240 antiviral activity by determining viral titres as TCID50/mL and viral antigens by ic ELISA 241 ( Figure 4A , B). As expected, the strongest reduction in viral titres was observed upon pre-242 treatment with IFNα5 as cells become alerted towards an antiviral state and antiviral effectors 243 can be transcribed or even translated prior to viral infection ( Figure 4B ). Intriguingly, even after 244 viral infection was established, treatment with IFNα5 was able to significantly reduce viral titres 245 ( Figure 4B ), which was also observed with the antiviral drug remdesivir (Extended Data Figure  246 8A). Given the clear antiviral but incomplete inhibitory effect of both treatment modalities, we 247 next studied a potential beneficial effect of IFNα5 when co-administered with remdesivir (see 248 Figure 4A for a schema). To this end, we analysed the antiviral effect upon pre-treatment as 249 well as post-treatment of an established infection. To quantify the interaction between the two 250 antiviral drugs, the observed combination response was compared to the expected effect using 251 the Loewe additivity model, with δ-scores above 10 indicating synergistic effects. Combination 252 therapies in VeroE6 cells revealed an additive antiviral activity, with over 90 % viral inhibition 253 upon pre-treatment in the highest concentrations of both drugs tested and a Loewe synergistic 254 score of 8.504 ( Figure 4C , D) without any effect on cytotoxicity (Extended Data Figure 8B IFNα subtypes, which are highly conserved, and they all signal through the same ubiquitously 283 expressed IFNAR1/2. Activation of various downstream signalling cascades implicates that the 284 IFNα subtypes share some overlapping functions, but also possess unique properties. Upon pre-285 treatment of cells with twelve distinct IFN subtypes, we observed cluster-specific antiviral 286 patterns which were distinct between different viruses. These differential antiviral functions 287 cannot be explained solely by the binding affinity to both receptor subunits as IFNα5 and IFNα4 288 exhibit a median affinity to IFNAR1 and IFNAR2 in the range of 0.94-3 µM and 2.1-3.8 nM, 289 respectively 12 . Furthermore, the increased gene induction did not correlate with binding affinity 290 to IFNAR1 or 2, as those IFNs with the highest binding affinity to IFNAR2 (IFNα10, 17, 6, 14, 7) did not induce significantly higher numbers of differentially expressed genes. In IFN-treated 292 gut biopsies of chronically HIV-infected patients, the numbers of induced genes by different 293 type I IFNs (IFNα1, α2, α5, α8, α14 and β) were not associated with binding affinity or ISRE 294 activation 49 . Importantly, it has been shown that the different type I IFNs induced a specific 295 pattern of genes, which are involved in various biological processes 49 . We observed distinct 296 antiviral patterns, that could be clearly clustered into high, intermediate and low antiviral effects 297 against SARS-CoV-2. Interestingly, we identified 19 genes that were common between all 298 groups, indicative of a basal IFN response. On top of that basal response, we identified several 299 genes that were distinct-, intersecting-or commonly differentially regulated between the high 300 and/or medium group. Our dataset enabled us to identify expression patterns that can be 301 correlated with antiviral activity against SARS-CoV-2. Foremost, antiviral immune responses 302 were significantly dysregulated in the moderate and high antiviral groups. Nevertheless, several 303 biological processes e.g. such associated with protein localization, translation or ER stress, 304 (2017). 552

IFNα subtypes were produced and purified as previously described 7 . The activity of each 555 subtype was determined using the human ISRE-Luc reporter cell line, a retinal pigment 556 epithelial cell line transfected with a plasmid containing the Firefly Luciferase gene, stably 557 integrated under control of the IFN-stimulation-response element (ISRE). Following 558 stimulation with IFNα, chemiluminescence can be detected and used to calculate the respective 559 activity in units against commercially available IFNα (PBL assays sciences, Piscataway, 560 USA) 7 . 561 562

VeroE6 cells were seeded at a density of 10,000 cells per well in a 96-well plate and maintained 564 in 200 µl DMEM (Gibco) supplemented with 10% fetal bovine serum (Sigma-Aldrich), L-565 glutamine (Gibco), penicillin and streptomycin (Gibco) overnight. The next day, 22 µl of virus 566 stock or apical washes of hAEC were added to the first row of the plate (6 replicates). Then, 567 the virus was diluted 1:10 by mixing the media and pipetting 22 µl to the next row repeatedly, 568 followed by 72 h incubation in 37°C in a 5% CO2 atmosphere. Thereafter, the supernatant was 569 aspirated and the cells were incubated in 100 µl of crystal violet solution (0.1 % crystal violet 570 (Roth) in PBS, 10% ethanol, 0.37% formalin) for 5 min. Subsequently, the crystal violet 571 solution was aspirated, cells were washed with PBS and the number of wells with intact or 572 damaged cell layer were determined. The TCID50/mL was calculated by the Spearman & Kärber 573 algorithm. 574 575 IFN titration assay 576 VeroE6 cells were seeded at a density of 10,000 cells per well in a 96-well plate and maintained 577 in DMEM supplemented with 10% fetal bovine serum, L-glutamine, penicillin and streptomycin overnight. Then, the medium was aspirated and serially diluted IFNα and IFNλ3 579 (R&D Systems) and virus with a final concentration of 350 PFU/mL were added to the cells in 580 a total volume of 100 µl of cell culture media, followed by 72 h incubation in 37°C in a 5% 581 CO2 atmosphere. Thereafter, the supernatant was aspirated and the cells were incubated in 100 582 µl of crystal violet solution (0.1 % crystal violet in PBS, 10% ethanol, 0.37% formalin) for 5 583 min. Subsequently, the crystal violet solution was aspirated, cells were washed with PBS and 584 the number of wells with intact or damaged cell layer were determined. 585

The inhibitory concentration 50 (IC50) was calculated using GraphPad Prism 6. 586 587

The in-cell (ic) ELISA was performed based on the previously published protocol (Scholer et 589 al., 2020) . VeroE6 cells were seeded at a density of 20,000 cells per well in a 96-well plate and 590 maintained in DMEM supplemented with 10% fetal bovine serum, L-glutamine, penicillin and 591 streptomycin. At indicated time points, the medium was aspirated and serially diluted IFNα or 592 the indicated concentrations of remdesivir and virus with a final concentration of 350 PFU/mL 593 were added to the cells in a total volume of 100 µl, followed by 24 h incubation in 37°C in a 594

Extended Data Fig. 6: Proteomic analysis results in differential switched on/off proteins 962

Proteomic analysis of IFN-treated and/or SARS-CoV-2-infected hAECs. (A) Differentially 963 regulated or induced (on IFN compared to untreated) proteins in IFN-stimulated hAECs at t=0h

at t=72h (mock) (B) or at t=72h (CoV-2) (C). Heatmaps of on-off

at t=72 h (mock) (E) or at t=72 h (CoV-2) (F)

We would like to thank all member of the Department for Molecular and Medical Virology of 862

were added for a minimum of 2 h at room temperature to fix the cells and inactivate the virus. 596Afterwards, the plate was washed thrice with PBS. The PBS was aspirated and 200 µl of freshly 597 prepared permeabilization buffer (PBS, 1% Triton X-100 (Roth)) were added to the cells and 598 the plate was incubated for 30 min at room temperature with constant shaking. Subsequently, 599 the permeabilization buffer was aspirated and 200 µl of blocking buffer (PBS, 3% FBS) were 600 added for 1 h. Then, the blocking buffer was aspirated and 50 µl of primary antibody solution 601(anti-SARS-CoV-2-NP (RRID: AB_2890255) 1:5000 diluted in PBS + 1% FBS) was added to 602 each well. The plate was incubated overnight at 4°C. The next day, the primary antibody 603 solution was aspirated and the plate was washed thrice with wash buffer (PBS, 0.05% Tween 604 20 (Roth)). Thereafter, 50 µl of the secondary antibody solution (Peroxidase-AffiniPure Goat 605Anti-Mouse IgG (H+L) (RRID: AB_10015289) 1:2000 in PBS, 1% FBS) was added to the 606 wells and the plate was incubated for 2 h at room temperature. After the incubation period, the 607 wells were washed 4 times with 250 µl wash buffer. Afterwards 100 µl of TMB substrate 608 solution (BioLegend) were added and the plate was incubated about 20 min at room temperature 609 in the dark. The reaction was stopped by addition of 100 µl 2N H2SO4 (Roth). The absorbance 610 was measured at 450 nm with a reference wavelength of 620 nm using Spark® 10M multimode 611 microplate reader (Tecan). 612 613

To exclude cytotoxic effects of the compounds used in our assays, a cell viability assay was 615 performed using the Orangu™ Cell Counting Solution (CELL guidance systems) according to 616 the manufacturer's instructions. The cells were seeded and treated equally to the protocol that 617 was used before without any viral infection. Afterwards, 10 µl of Orangu™ Cell Counting 618Solution were added to each well and the plate was incubated for 2 h. Then, the absorbance was 619 measured at 450 nm with Spark® 10M multimode microplate reader. 620 621 Immunofluorescence 622VeroE6 cells were seeded and treated as described for the in-cell ELISA. and stored in PBS supplemented with antibiotics (penicillin 100 U/mL, streptomycin 100 639 µg/mL, 10 µg/mL ciprofloxacin (Kabi)). HAEC were isolated from the mucosa within 24 h 640 after transplantation by enzymatic digestion (Protease XIV (Sigma Aldrich)) and scraping. 641Cells were expanded for 7-14 days in KSFM (keratinocyte-SF-medium (Gibco), supplemented 642 with human epidermal growth factor (Gibco) (2.5 ng/mL), bovine pituitary extract (Gibco) 643 (BPE 25 µg/mL, Gibco), isoproterenol (Sigma-Aldrich) (1µM), Penicillin, Streptomycin, 644Ciprofloxacin, Amphotericin B (PanBiotech) (2,5 µg/mL)) and after trypsinization stored in 645 liquid nitrogen (10% DMSO, 90% KSFM+BPE 0,3mg/mL). All plastic surfaces during hAEC 646 isolation and air liquid interface (ALI) culture were coated with human fibronectin (PromoCell) 647 (5 µg/mL), type I bovine collagen (Advanced BioMatrix) (PureCol 30 µg/mL) and BSA (10 648 µg/mL). For ALI cultures, cells were thawed, expanded in KSFM for 5-7 days and transferred 649 to transwell inserts (PE Membrane, 12 well plates, 0.4 µm pore size, Corning). sapiens and SARS-CoV-2. Search parameters were default, LFQ was used for peak 744 quantification and normalization was enabled. Peptides were considered for quantification 745 irrespective of modifications. Match between runs was enabled when the analysis was 746 performed considering human proteins only. Statistical data analysis was conducted using R 747 (v.3.6.2). Differences between the experimental groups were assessed using t-tests (paired, two-748 sided) and proteins quantified in minimum 3 of 4 donors per group with minimum 2 unique 749 peptides, a p-value ≤ 0.05 and a ratio of mean abundances ≥ 1.5 or ≤ 0.67 were considered 750 statistically significant. Proteins that were quantified in one experimental group but not detected 751 at all in an opposed group were defined as On-Offs between these groups. GO annotation and 752 enrichment analyses were performed using STRING (v.11 OmicSoft Aligner OSA 62 . Differential gene expression of each condition was assessed using 774 DESeq2 63 . Differentially expressed genes were sent to Ingenuity Pathway Analysis (IPA) 775 (https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/analysis-776 and-visualization/qiagen-ipa/) for biological analysis using the cutoffs: p-value <0.05, fold 777 change (fc) >|1.5| and mean counts min>5. IPA statistics is based on two outputs. A p-value 778 derived from a right-tailed Fisher's Exact Test estimates the probability that the association 779 between a function or pathway and a set of molecules might be due to random chance but does 780 not consider directional changes. This is, however, predicted for a disease and/or function, 781 canonical pathway, or upstream regulator (activation or inhibition) by the activation z-score 782 algorithm. The z-score describes the number of standard deviations data lies above or below 783 the mean. A z-score >2 was considered significantly increased whereas a z-score<-2 was 784 considered significantly decreased 64 . We performed an expression analysis to evaluate 785 transcriptomic changes for Canonical Pathways in each of the comparison IFN vs mock 64 . 786 787

Differences in transformed data were tested for significance using GraphPad Prism v8.4.2 for 789 Windows (GraphPad). Statistically significant differences between the IFNα-treated groups and 790 the untreated group were analyzed using Ordinary One-Way ANOVA analysis with Dunnetts's 791 multiple comparison test. P values < 0.05 were considered significant. (IFNα5); **** p<0.0001 (IFNα14, IFNλ3); 1000 U/mL (ng/mL): * p=0.0180 (IFNα17); **** 808 p<0.0001 (IFNα4, α5, α14, λ3) . G: 100 U/mL (ng/mL): * p=0.0352 (IFNα14); ** p=0.0063 809 (IFNα2) *** p=0.0002 (IFNα4); **** p<0.0001 (IFNα5, IFNλ3); 1000 U/mL (ng/mL): ** 810 p=0.0028 (IFNα2) p=0.0016 (IFNα17) A: RNA copies /50ng: * p=0.0228 (1000U/mL IFNα4); * p=0.0110 (1000U/mL IFNα21); ** 906 p=0.0021 (1000U/mL IFNα5); *** p=0.0008 (1000U/mL IFNα14); RNA copies/5µl : * 907 p=0.0106 (100U/mL IFNα14); ** p=0.0050 (100U/mL IFNα5); ** p=0.0017 (1000ng/mL 908 IFNλ3); *** p=0.0002 (1000U/mL IFNα4); **** p<0.0001 (1000U/mL IFNα5, α14) 909 E: 100 U/mL (ng/mL): **** p<0.0001 (IFNα5, λ3); 1000 U/mL (ng/mL): * p=0.0184 910 (IFNα14); *** p=0.0003 (IFNα4) **** p<0.0001 (IFNα5, λ3); F: 100 U/mL (ng/mL): * 911 p=0.0289 (IFNα2); ** p=0.0032 (IFNα4)**** p<0.0001 (IFNα5, λ3); 1000 U/mL (ng/mL): ** 912 p=0.0019 (IFNα14); **** p<0.0001 (IFNα4, α5, λ3); 913 G: 48h: * p= 0.0120 (IFNα2); *** p= 0.0001 (IFNα4); *** p= 0.0002 (IFNα14); **** p<0.0001 914 (IFNα5, λ3); 72h: ** p= 0.0034 (IFNα2); **** p<0.0001 (IFNα4, α5